Risk Factors for Mucosal Ulceration in Gastric Gastrointestinal Stromal Tumors (GIST)
Eran Ariam, Anton Bermont, Yehuda Herskovitz, Shay Matalon, Bard Vyacheslav, Reut Yaakobi, Daana Baseem, Fadi Younis, Asia Zubkov, Efrat Broide, Benjamin Avidan, Steven F Moss and Haim Shirin
Article Type: Case Report | First Published: November 18, 2019
Gastrointestinal stromal tumors (GIST) are the most common subepithelial tumors in the gastrointestinal (GI) tract and they are usually located in the stomach. To date, only a few studies have investigated the risk factors for GIST ulceration and bleeding and there have been no prior publications focused on role of Helicobacter pylori in GIST ulceration. The aim of current study was to investigate the risk factors of mucosal ulceration in gastric GISTs. A retrospective study was conducted of 130...
Successful Treatment of Hepatitis C, Genotype 3, Treatment Failure (Sofosbuvir/Daclatasvir) with Sofosbuvir/Velpatasvir in Decompensated Cirrhosis Complicated by Renal Insufficiency
Marco Distefano, Lorenza Di Marco, Enzo Scifo, Salvatore Gruttadauria, Gaetano Scifo and Vito Di Marco
Article Type: Case Report | First Published: September 30, 2019
Clinical trials and real word data have proven that chronic hepatitis C (HCV) can be eradicated (sustained virological response SVR or ‘cure’) in the majority of patients by direct - acting antivirals (DAAs) . There are, however, groups of patients in whom HCV treatment outcomes with direct acting antivirals (DAAs) are suboptimal (genotype (GT) 3 patients, decompensated cirrhosis, renal failure) or have not been studied in large cohorts (patients with relapse to a previous DAAs treatment (fa...